What is Zacks Research's Forecast for BIO FY2026 Earnings?

Key Points

• Zacks Research has revised its FY2026 earnings per share estimate for Bio-Rad Laboratories down to $10.36, from a previous estimate of $10.43, maintaining a "Hold" rating on the stock.
• Wells Fargo and Royal Bank of Canada increased their price targets for Bio-Rad shares, with Wells Fargo raising it to $265.00 and Royal Bank of Canada to $409.00.
• Bio-Rad's stock opened at $283.63, with a 1-year high of $387.99 and a market capitalization of $7.68 billion.

Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Zacks Research decreased their FY2026 earnings per share (EPS) estimates for shares of Bio-Rad Laboratories in a report released on Monday, September 22nd. Zacks Research analyst Team now anticipates that the medical research company will post earnings per share of $10.36 for the year, down from their previous forecast of $10.43. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q4 2026 earnings at $2.62 EPS.

BIO has been the topic of several other research reports. Wells Fargo & Company upped their price target on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Royal Bank Of Canada upped their target price on Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an "outperform" rating in a research note on Friday, August 1st. Finally, Wall Street Zen cut Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Friday, August 22nd. Three analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $333.50.

Bio-Rad Laboratories Stock Performance

Bio-Rad Laboratories stock opened at $283.63 on Tuesday. Bio-Rad Laboratories has a 1-year low of $211.43 and a 1-year high of $387.99. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $7.68 billion, a PE ratio of 24.18 and a beta of 0.95. The firm's 50 day simple moving average is $275.86 and its 200 day simple moving average is $252.83.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.93 by $0.68. The firm had revenue of $651.60 million for the quarter, compared to the consensus estimate of $614.82 million. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The company's revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm posted $3.11 earnings per share. Bio-Rad Laboratories has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Nuveen Asset Management LLC boosted its position in Bio-Rad Laboratories by 0.8% during the 4th quarter. Nuveen Asset Management LLC now owns 39,505 shares of the medical research company's stock valued at $12,978,000 after buying an additional 327 shares during the period. ProShare Advisors LLC raised its stake in shares of Bio-Rad Laboratories by 8.0% during the fourth quarter. ProShare Advisors LLC now owns 901 shares of the medical research company's stock valued at $296,000 after acquiring an additional 67 shares during the last quarter. Tidal Investments LLC raised its stake in shares of Bio-Rad Laboratories by 21.1% during the fourth quarter. Tidal Investments LLC now owns 1,069 shares of the medical research company's stock valued at $351,000 after acquiring an additional 186 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Bio-Rad Laboratories by 70.3% during the fourth quarter. Two Sigma Investments LP now owns 2,050 shares of the medical research company's stock worth $673,000 after purchasing an additional 846 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of Bio-Rad Laboratories during the fourth quarter worth about $2,211,000. 65.24% of the stock is owned by hedge funds and other institutional investors.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.